The challenge of developmental therapeutics for adrenocortical carcinoma.

Details

Serval ID
serval:BIB_11B5DD3C317E
Type
Article: article from journal or magazin.
Collection
Publications
Title
The challenge of developmental therapeutics for adrenocortical carcinoma.
Journal
Oncotarget
Author(s)
Costa R., Carneiro B.A., Tavora F., Pai S.G., Kaplan J.B., Chae Y.K., Chandra S., Kopp P.A., Giles F.J.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Publication state
Published
Issued date
19/07/2016
Peer-reviewed
Oui
Volume
7
Number
29
Pages
46734-46749
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/β-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.
Keywords
Adrenal Cortex Neoplasms/drug therapy, Adrenal Cortex Neoplasms/etiology, Adrenocortical Carcinoma/drug therapy, Adrenocortical Carcinoma/etiology, Humans, Molecular Targeted Therapy, Receptor, IGF Type 1/antagonists & inhibitors, Receptor, IGF Type 1/physiology, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Receptors, Vascular Endothelial Growth Factor/physiology, Signal Transduction, TOR Serine-Threonine Kinases/antagonists & inhibitors, IGF-1R, VEGFR, adrenocortical carcinoma, targeted therapy, β-catenin
Pubmed
Web of science
Open Access
Yes
Create date
27/12/2020 13:55
Last modification date
28/12/2020 6:26
Usage data